Charles River Laboratories (CRL)
EBITDA Growth
-58.27%
TTM · Period ending:
CRL EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-58.27%period ending
Latest reported-58.27%period ending
CRL TTM EBITDA YoY % (41.62% → -58.27%)
Year-over-year change
High-resolution chart · PNG
CRL ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| -58.2748% | |
| -46.7833% | |
| -29.3052% | |
| -47.8541% | |
| -47.4827% | |
| -45.8869% | |
| -43.6941% | |
| -7.1479% | |
| -4.1972% | |
| -2.3292% | |
| 4.6616% | |
| 22.4102% | |
| 20.6218% | |
| 20.3737% | |
| 20.2385% | |
| 3.2163% | |
| 2.4913% | |
| 7.5163% | |
| 6.7262% | |
| 23.4578% | |
| 41.4056% | |
| 40.2314% | |
| 36.4809% | |
| 32.8579% | |
| 15.9581% | |
| 9.1645% | |
| 11.0066% | |
| 6.31% | |
| 11.6298% | |
| 16.4181% | |
| 10.7757% | |
| 6.5395% | |
| 6.7439% | |
| 8.1045% | |
| 21.3638% | |
| 29.877% | |
| 29.3012% | |
| 26.1407% | |
| 23.5467% | |
| 18.6049% | |
| 17.1071% | |
| 18.3627% | |
| 6.7803% | |
| 8.3545% | |
| 5.857% | |
| 7.6275% | |
| 11.7445% | |
| 6.3997% | |
| 12.3753% | |
| 5.3584% | |
| 4.7344% | |
| 1.218% | |
| -4.5881% | |
| -5.9204% | |
| -6.1867% | |
| 279.0268% | |
| 248.5429% | |
| 234.6673% | |
| 228.0393% | |
| -174.1735% | |
| -173.197% | |
| -175.5179% | |
| -176.9594% | |
| 145.7042% | |
| 158.8556% | |
| 167.8935% | |
| 175.2736% | |
| -219.0248% | |
| -214.8812% | |
| -214.655% | |
| -211.0937% | |
| 13.6885% | |
| 16.6518% | |
| 15.2126% | |
| 118.0906% | |
| 119.1221% | |
| 97.7331% | |
| 92.1002% | |
| -49.118% | |
| -49.513% | |
| -39.8397% | |
| -36.0827% | |
| 36.6246% | |
| 41.8314% | |
| 33.1633% | |
| 31.7143% | |
| 22.8821% | |
| 20.1718% | |
| 15.8849% | |
| 13.9145% | |
| 14.65% | |
| 15.9407% | |
| 20.8843% | |
| 21.1168% | |
| 24.5093% | |
| 31.8676% | |
| 35.9121% | |
| 48.0054% | |
| 41.6175% |